OVERVIEW
Prostate Cancer
TRI researchers are dedicated to finding solutions to help the 20,000 plus Australian men diagnosed and 3,300 who will die from prostate cancer every year, and to improve clinical management of prostate cancer in Australia.
The following groups are undertaking prostate cancer research at TRI:
- Led by Professor Colleen Nelson and based at TRI, the Australian Prostate Cancer Research Centre - Queensland (APCRC-Q) spans the spectrum of prostate cancer research - discovery, prognostic biomarker and therapeutic development - through the expertise and passion of a large, coordinated, multidisciplinary research team, underpinned by leading technology. For more information on APCRC-Q, please visit http://www.australianprostatecentre.org/.
- UQDI’s Dr Michelle Hill is working on a prostate cancer diagnostic which could identify or predict metastisis, the process by which cancer spreads to other organs. Metastatic prostate cancer is more life-threatening and requires more aggressive treatment.
- QUT's Associate Professor Jyotsna Batra and her team are working on ways to increase the accuracy of the Prostate Specific Antigen (PSA) test, the main tool used for prostate cancer screening. A/Prof Batra was named Cure Cancer Researcher of the Year in 2018.
- Professor Pamela Russell and her team are developing a combinations of diagnostics and therapy to develop 'theranostics' to improve diagnosis and treatment of prostate cancer. Read more.
Key Researchers
Michelle M Hill
Brett Hollier
Colleen Nelson
Elizabeth Williams
Jyotsna Batra
Show More ...
Key Aims
- Develop new therapies for advanced disease, with an emphasis on rationalised combination strategies with androgen targeted agents and prostate cancer progression pathways.
- Identify, validate and develop biomarkers for genetic predisposition, prognostication to differentiate indolent from aggressive disease, therapeutic response indicators to inform treatment options and planning.
GALLERY
APCRC Laboratory
APCRC Laboratory
APCRC Laboratory
